These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Wilms' tumor 1 gene in hematopoietic malignancies: clinical implications and future directions. Luo P; Jing W; Yi K; Wu S; Zhou F Leuk Lymphoma; 2020 Sep; 61(9):2059-2067. PubMed ID: 32401109 [TBL] [Abstract][Full Text] [Related]
27. Wilms' tumor suppressor gene WT1: from structure to renal pathophysiologic features. Mrowka C; Schedl A J Am Soc Nephrol; 2000 Nov; 11 Suppl 16():S106-15. PubMed ID: 11065340 [TBL] [Abstract][Full Text] [Related]
28. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1. Zaia A; Fraizer GC; Piantanelli L; Saunders GF Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720 [TBL] [Abstract][Full Text] [Related]
29. Expression of the Wilms' tumor gene (WT1) in human leukemias. Miwa H; Beran M; Saunders GF Leukemia; 1992 May; 6(5):405-9. PubMed ID: 1317488 [TBL] [Abstract][Full Text] [Related]
30. Expression of the Wilms' tumor suppressor gene, WT1, reduces the tumorigenicity of the leukemic cell line M1 in C.B-17 scid/scid mice. Smith SI; Down M; Boyd AW; Li CL Cancer Res; 2000 Feb; 60(4):808-14. PubMed ID: 10706085 [TBL] [Abstract][Full Text] [Related]
31. Analysis of native WT1 protein from frozen human kidney and Wilms' tumors. Iben S; Royer-Pokora B Oncogene; 1999 Apr; 18(15):2533-6. PubMed ID: 10229205 [TBL] [Abstract][Full Text] [Related]
32. Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Loeb DM; Evron E; Patel CB; Sharma PM; Niranjan B; Buluwela L; Weitzman SA; Korz D; Sukumar S Cancer Res; 2001 Feb; 61(3):921-5. PubMed ID: 11221883 [TBL] [Abstract][Full Text] [Related]
33. Frequency and heritability of WT1 mutations in nonsyndromic Wilms' tumor patients: a UK Children's Cancer Study Group Study. Little SE; Hanks SP; King-Underwood L; Jones C; Rapley EA; Rahman N; Pritchard-Jones K J Clin Oncol; 2004 Oct; 22(20):4140-6. PubMed ID: 15483024 [TBL] [Abstract][Full Text] [Related]
34. p53 gene alterations in human hematological malignancies: a review. Soussi T; Jonveaux P Nouv Rev Fr Hematol (1978); 1991; 33(6):477-80. PubMed ID: 1818301 [TBL] [Abstract][Full Text] [Related]
35. Molecular cytogenetic aspects of hematological malignancies: clinical implications. Chen Z; Sandberg AA Am J Med Genet; 2002 Oct; 115(3):130-41. PubMed ID: 12407693 [TBL] [Abstract][Full Text] [Related]
36. Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. King-Underwood L; Pritchard-Jones K Blood; 1998 Apr; 91(8):2961-8. PubMed ID: 9531607 [TBL] [Abstract][Full Text] [Related]
37. Mutation analysis of the WT1 gene in myelodysplastic syndromes. Hosoya N; Miyagawa K; Mitani K; Yazaki Y; Hirai H Jpn J Cancer Res; 1998 Aug; 89(8):821-4. PubMed ID: 9765617 [TBL] [Abstract][Full Text] [Related]
38. Wilms' tumor-1 transcript in peripheral blood helps diagnose acute myeloid leukemia and myelodysplastic syndrome in patients with pancytopenia. Yamauchi T; Matsuda Y; Takai M; Tasaki T; Hosono N; Negoro E; Ikegaya S; Takagi K; Kishi S; Yoshida A; Urasaki Y; Ueda T Anticancer Res; 2012 Oct; 32(10):4479-83. PubMed ID: 23060576 [TBL] [Abstract][Full Text] [Related]
39. WT1: what has the last decade told us? Little M; Holmes G; Walsh P Bioessays; 1999 Mar; 21(3):191-202. PubMed ID: 10333728 [TBL] [Abstract][Full Text] [Related]
40. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity. Scharnhorst V; Menke AL; Attema J; Haneveld JK; Riteco N; van Steenbrugge GJ; van der Eb AJ; Jochemsen AG Oncogene; 2000 Feb; 19(6):791-800. PubMed ID: 10698497 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]